Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder
Sponsor: Mackay Memorial Hospital
Summary
To investigates the effects of solifenacin or mirabegron with local estrogen versus combination treatment with solifenacin and mirabegron in women with overactive bladder
Official title: Efficacy and Safety of Solifenacin or Mirabegron With Local Estrogen Versus Combination Treatment With Mirabegron and Solifenacin for Refractory Overactive Bladder
Key Details
Gender
FEMALE
Age Range
40 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2022-06-16
Completion Date
2026-12-31
Last Updated
2025-05-09
Healthy Volunteers
No
Interventions
Combined pharmacotherapy with Solifenacin and Mirabegron
Solifenacin (5mg) is anticholinergic and Mirabegron (25mg) is a beta-3 adrenergic agonist.
Solifenacin with vaginal estrogen cream
Solifenacin (5mg) is anticholinergic. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).
Mirabegron with vaginal estrogen cream
Mirabegron (25mg) is a beta-3 adrenergic agonist. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).
Locations (1)
Mackay Memorial Hospital
Taipei, Taiwan